Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

16
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
16
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

22
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
22
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

27
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
27
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

22
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
22
Disturbances in Heart Rhythm01:29

Disturbances in Heart Rhythm

1.1K
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
1.1K
Dysrhythmias IV: Characteristics of Bradyarrhythmias01:18

Dysrhythmias IV: Characteristics of Bradyarrhythmias

17
Bradyarrhythmias are cardiac rhythm disorders characterized by a slower-than-normal heart rate, typically defined as fewer than 60 beats per minute. Some of which are discussed here:Sinus BradycardiaSinus bradycardia presents a heart rate lower than 60 beats per minute, with a regular rhythm originating from the SA node. The ECG typically shows normal P waves preceding each QRS complex, a normal PR interval (0.12 to 0.20 seconds), and a normal QRS duration (0.06 to 0.10 seconds).First-Degree AV...
17

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sodium zirconium cyclosilicate post hospital discharge to prevent hyperkalaemia: phase 4, randomized CONTINUITY trial.

Clinical kidney journal·2026
Same author

Comprehensive clinical benefit of CCM in HFrEF patients: a win-ratio analysis of FIX-HF-5C randomized trial.

ESC heart failure·2026
Same author

A new and impactful ESC initiative: ESC Eastern Countries Task Force.

European heart journal·2026
Same author

Access to cardiac implantable electronic device therapy in the ESC EuroAsia region: a comparative analysis of implantation activity, infrastructure, and health financing.

European heart journal. Quality of care & clinical outcomes·2026
Same author

Multidisciplinary approach to implementing ferric carboxymaltose for IV iron replacement in heart failure with iron deficiency.

Future cardiology·2026
Same author

A General Framework for Designing and Evaluating Active-Controlled Trials with Non-Inferiority Objectives.

Statistics in medicine·2026

Related Experiment Video

Updated: Aug 12, 2025

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.5K

Cardiac Resynchronization Therapy Improves Outcomes in Patients With Intraventricular Conduction Delay But Not Right

Daniel J Friedman1,2, Sana M Al-Khatib1,2, Frederik Dalgaard2,3

  • 1Division of Cardiology (D.J.F., S.M.A-K., M.F.), Duke University School of Medicine, Durham, NC.

Circulation
|January 26, 2023
PubMed
Summary

Cardiac resynchronization therapy (CRT) effectively reduces heart failure hospitalization or death in patients with left bundle branch block (LBBB) or intraventricular conduction delay (IVCD) and QRS duration ≥150 ms. Right bundle branch block (RBBB) did not show a significant benefit.

Keywords:
bundle-branch blockcardiac resynchronization therapydefibrillators, implantablemeta-analysis

More Related Videos

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

811
Ablation of Ischemic Ventricular Tachycardia Using a Multipolar Catheter and 3-dimensional Mapping System for High-density Electro-anatomical Reconstruction
06:57

Ablation of Ischemic Ventricular Tachycardia Using a Multipolar Catheter and 3-dimensional Mapping System for High-density Electro-anatomical Reconstruction

Published on: January 31, 2019

14.8K

Related Experiment Videos

Last Updated: Aug 12, 2025

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.5K
Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

811
Ablation of Ischemic Ventricular Tachycardia Using a Multipolar Catheter and 3-dimensional Mapping System for High-density Electro-anatomical Reconstruction
06:57

Ablation of Ischemic Ventricular Tachycardia Using a Multipolar Catheter and 3-dimensional Mapping System for High-density Electro-anatomical Reconstruction

Published on: January 31, 2019

14.8K

Area of Science:

  • Cardiology
  • Electrophysiology
  • Heart Failure Management

Background:

  • Cardiac resynchronization therapy (CRT) effectiveness varies based on QRS characteristics.
  • Individual clinical trials often lack the statistical power to analyze CRT benefits in smaller patient subgroups defined by QRS morphology and duration.

Purpose of the Study:

  • To assess the benefit of cardiac resynchronization therapy (CRT) across different QRS morphologies (LBBB, RBBB, IVCD) and durations using pooled patient-level data.
  • To determine the continuous relationship between QRS duration and CRT benefit within specific QRS morphology subgroups.

Main Methods:

  • Patient-level data from eight pivotal CRT trials were analyzed.
  • Bayesian Hierarchical Weibull survival regression models were employed to assess CRT benefit.
  • Primary endpoint: time to heart failure hospitalization (HFH) or death; Secondary endpoint: time to all-cause death.

Main Results:

  • CRT was associated with a reduced risk of HFH or death (HR 0.73).
  • Significant benefits were observed in patients with QRS ≥150 ms and LBBB (HR 0.56) or IVCD (HR 0.59), but not RBBB (HR 0.97).
  • No significant CRT benefit was found for QRS duration <150 ms or in the presence of RBBB, regardless of QRS duration.

Conclusions:

  • Cardiac resynchronization therapy (CRT) demonstrates reduced heart failure hospitalization or death in patients with QRS duration ≥150 ms and LBBB or IVCD.
  • Patients with RBBB do not appear to benefit from CRT based on these QRS characteristics.
  • Reconsideration of grouping RBBB and IVCD into a single 'non-LBBB' category for CRT patient selection is recommended.